Naringin protects endothelial cells from apoptosis and inflammation by regulating the Hippo-YAP Pathway

Biosci Rep. 2020 Mar 27;40(3):BSR20193431. doi: 10.1042/BSR20193431.

Abstract

Atherosclerosis is the primary cause of several cardiovascular diseases. Oxidized low-density lipoprotein (ox-LDL)-induced apoptosis, endothelial-mesenchymal transition (EndMT), and inflammation are crucial for the progression of cardiovascular diseases, including atherosclerosis. Naringin, a major compound from tomatoes, grapefruits, and related citrus, reportedly exhibits potential protective effects during atherosclerosis development; however, its effect on ox-LDL-induced human umbilical vein endothelial cell (HUVEC) damage remains unknown. In the present study, we investigated the anti-apoptotic and anti-inflammatory activities of naringin against ox-LDL-induced endothelial cells, and the underlying mechanism. Naringin pretreatment significantly and concentration-dependently inhibited ox-LDL-induced cell injury and apoptosis. Additionally, naringin restored endothelial barrier integrity by preventing VE-cadherin disassembly and F-actin remodeling, and down-regulated pro-inflammatory factors like IL-1β, IL-6, and IL-18, in the HUVECs. We also demonstrated that naringin treatment restored ox-LDL-induced YAP (yes-associated protein) down-regulation, given the YAP-shRNA attenuated cytoprotective effect of naringin on ox-LDL-induced endothelial cell injury and apoptosis. Collectively, our data indicate that naringin reversed ox-LDL-triggered HUVEC apoptosis, EndMT, and inflammation by inhibiting the YAP pathway. Therefore, naringin may have a therapeutic effect on endothelial injury-related disorders.

Keywords: Endothelial cells; Hippo-YAP Pathway; Naringin; apoptosis; inflammation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism
  • Anti-Inflammatory Agents / pharmacology
  • Antioxidants / pharmacology
  • Apoptosis / drug effects
  • Atherosclerosis / drug therapy
  • Atherosclerosis / genetics
  • Cell Survival / drug effects
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Flavanones / metabolism
  • Flavanones / pharmacology*
  • Hippo Signaling Pathway
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Inflammation / metabolism
  • Lipoproteins, LDL / adverse effects
  • Oxidative Stress / drug effects
  • Protein Serine-Threonine Kinases / metabolism
  • Signal Transduction / drug effects
  • Transcription Factors / metabolism
  • YAP-Signaling Proteins

Substances

  • Adaptor Proteins, Signal Transducing
  • Anti-Inflammatory Agents
  • Antioxidants
  • Flavanones
  • Lipoproteins, LDL
  • Transcription Factors
  • YAP-Signaling Proteins
  • YAP1 protein, human
  • oxidized low density lipoprotein
  • Protein Serine-Threonine Kinases
  • naringin